Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Ginsenoside Rg1 as a Promising Adjuvant Agent for Enhancing the Anti-cancer Functions of Granulocytes Inhibited by Noradrenaline

PROVIDER: PRJNA929088 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23263612_1.fastq.gz	Fastqsanger.gz
	SRR23263612_2.fastq.gz	Fastqsanger.gz
	SRR23263613_1.fastq.gz	Fastqsanger.gz
	SRR23263613_2.fastq.gz	Fastqsanger.gz
	SRR23263614_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Project description:Ginsenoside Rg1

| PRJNA726376 | ENA

Expression data from MCF-7 breast cancer cells treated with CNTs, ginsenosides (Rb1 and Rg1) and conjugates (Rb-CNTs and Rg-CNTs)

Project description:To investigate the effects of ginsenosides-CNTs conjugtaes on total expression profile of MCF-7 breast cancer cells, we conjugated ginsenoides Rb1 and Rg1 with multi-walled carbon nanotubes in a 5:1 ratio. Objectives for this study included the identification of genes that were up or down-regulated at the transcriptional level in MCF-7 cells treated with ginsenoside-CNTs conjugates and compare it to the ginsenosides alone (Rb1 and Rg1)

2016-12-15 | GSE75570 | GEO

Role of MicroRNA-214 in Ginsenoside-Rg1-induced Angiogenesis

Project description:MicroRNAs (miRNAs) are small non-coding RNAs that act as post-transcriptional gene modulators. Ginsenoside-Rg1, one of the active components of ginseng, has been confirmed by us as an angiogenesis inducer. Using miRNA microarray analysis, a total of 15 (including miR-214) and 3 miRNAs were found to be down- or up-regulated by Rg1 in human umbilical vein endothelial cells (HUVEC), respectively. Since miR-214 is closely related to endothelial nitric oxide synthase (eNOS) and hence angiogenesis; its expression was further validated by qRT-PCR. We also investigated the role of miR-214 on eNOS expression and in tubulogenesis of HUVEC by transfection of specific miRNA inhibitor or precursor. Our results suggested that Rg1 can down-regulate miR-214 expression in HUVEC, leading to an increase in eNOS expression which can promote angiogenesis. This result signifies a new understanding towards how a simple natural compound can affect physiological changes through modulation of miRNA expression. The study is used to investigate the role of miRNA-214 in Rg1-induced human endothelial cells.

2010-08-05 | E-GEOD-17541 | biostudies-arrayexpress

Role of MicroRNA-214 in Ginsenoside-Rg1-induced Angiogenesis

2010-08-05 | GSE17541 | GEO

A systematic exploration on Ginsenoside Rg5 reveals proresolving functions in airway mucous cells.

Project description:Ginsenoside Rg5 reveals proresolving functions in airway mucous cells through inhibition of ROS production and promoting anti-inflammation factors

2023-01-25 | GSE173990 | GEO

Evaluation of pharmacological effects of ginsenoside Rk2 on hepatic ischemia/reperfusion-injury in vivo and in vitro [mouse]

Project description:Hepatic ischemia-reperfusion injury (IRI) poses a significant concern in conditions such as hemorrhagic shock, hepatic resection, and liver transplantation. Recent studies have highlighted the potential of phytomedicines and natural products in effectively protecting against various forms of IRIs. In this particular investigation, we conducted high-throughput screening and identified ginsenoside Rk2 (Rk2), a rare dehydroprotopanaxadiol saponin, as a promising agent for hepatic IRI. Our subsequent in vivo and in vitro studies demonstrated that Rk2 effectively mitigated inflammation and apoptosis induced by hepatic IRI in a dose-dependent manner. In this study, we comprehensively investigate the pharmacological effects of ginsenoside Rk2 in the treatment of hepatic IRI and elucidate potential molecular mechanisms in vivo.

2024-12-20 | GSE284060 | GEO

Evaluation of pharmacological effects of ginsenoside Rk2 on hepatic ischemia/reperfusion-injury in vivo and in vitro [HuH7]

Project description:Hepatic ischemia-reperfusion injury (IRI) poses a significant concern in conditions such as hemorrhagic shock, hepatic resection, and liver transplantation. Recent studies have highlighted the potential of phytomedicines and natural products in effectively protecting against various forms of IRIs. In this particular investigation, we conducted high-throughput screening and identified ginsenoside Rk2 (RK), a rare dehydroprotopanaxadiol saponin, as a promising agent for hepatic IRI. Our subsequent in vivo and in vitro studies demonstrated that Rk2 effectively mitigated inflammation and apoptosis induced by hepatic IRI in a dose-dependent manner. In this study, we comprehensively investigate the pharmacological effects of ginsenoside Rk2 in the treatment of hepatic IRI and elucidate potential molecular mechanisms in vitro.

2024-12-20 | GSE284059 | GEO

Homo sapiens

Project description:Role of MicroRNA-214 in Ginsenoside-Rg1-induced Angiogenesis

| PRJNA118533 | ENA

Project description:Transcriptome of ginsenoside anti-tumor.

| PRJNA546518 | ENA

Copper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma [GeoMx]

Project description:Anti-disialoganglioside (GD2) antibody therapy has provided clinical benefit to patients with neuroblastoma however efficacy is likely impaired by the immunosuppressive tumor microenvironment. We have previously defined a link between intratumoral copper levels and immune evasion. Here, we report that adjuvant copper chelation potentiates anti-GD2 antibody therapy to confer durable tumor control in immunocompetent models of neuroblastoma. Mechanistic studies reveal copper chelation creates an immune-primed tumor microenvironment through enhanced infiltration and activity of Fc-receptor-bearing cells, specifically neutrophils which are emerging as key effectors of antibody therapy. Moreover, we report copper sequestration by neuroblastoma attenuates neutrophil function which can be successfully reversed using copper chelation to increase pro-inflammatory effector functions. Importantly, we repurpose the clinically approved copper chelating agent Cuprior as a non-toxic, efficacious immunomodulatory strategy. Collectively, our findings provide robust evidence for the clinical testing of Cuprior as an adjuvant to enhance the activity of anti-GD2 antibody therapy and improve outcomes for patients with neuroblastoma.

2024-11-18 | GSE281844 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data